Company intelligence / Profile preview
Antennova
Doylestown, Pennsylvania, United Statesantennova.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Antennova has shown promising clinical results across its pipeline. ATN-022 demonstrated a 42.9% overall response rate in patients with advanced or metastatic gastric cancer. ATN-031 showed tumor shrinkage in a heavily pre-treated patient in its first dosing cohort with no dose-limiting toxicities reported. ATN-037 data is being presented at ESMO Congress 2024.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesSmall moleculesAntibody-drug conjugates (ADC)Bispecific antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Collaboration with The University of Texas MD Anderson Cancer Center
Beyond the preview
Go deeper on Antennova.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antennova.